Sun Pharma Advanced Research Company (SPARC) Q1 26/27 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board on August 10, 2026.

• Requests for reclassification of certain promoter group individuals to public category were approved, pending regulatory approvals.

Financial highlights

• Standalone revenue from operations for Q1 FY27 was ₹3,992 lakhs, compared to ₹964 lakhs in Q1 FY26 and ₹1,84,002 lakhs in Q4 FY26 (which included a one-time PRV sale).

• Standalone net loss for Q1 FY27 was ₹2,098 lakhs, versus a net loss of ₹5,203 lakhs in Q1 FY26 and a net profit of ₹1,76,070 lakhs in Q4 FY26.

• Consolidated revenue from operations for Q1 FY27 was ₹3,992 lakhs, with a consolidated net loss of ₹2,078 lakhs.

• Basic and diluted EPS for Q1 FY27 was ₹(0.65) standalone and ₹(0.64) consolidated.

Outlook and guidance

• No explicit forward-looking guidance provided, but recent developments such as the PRV sale and licensing agreement termination may impact future quarters.